Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. - Voelkel-Johnson,C.; King,D.L.; Norris,J.S. (Cancer Gene Ther, 2002)